# Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.

> **NCT00366249** · PHASE3 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 1061 (actual)

## Conditions studied

- Bacterial Infections
- Diabetic Foot
- Osteomyelitis

## Interventions

- **DRUG:** Tigecycline
- **DRUG:** Ertapenem

## Key facts

- **NCT ID:** NCT00366249
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 1061 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00366249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00366249, "Study Evaluating the Safety and Efficacy of a Once-daily Dose of Tigecycline vs Ertapenem in Diabetic Foot Infections (DFI) With a Substudy in Patients With Diabetic Foot Infections Complicated by Osteomyelitis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00366249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*